Clinical trial NCT00128310: Vinorelbine Versus Gemcitabine Plus Vinorelbine in Metastatic Breast Cancer Patients
Official title: Randomized Phase III Trial Comparing Vinorelbine vs. Gemcitabine Plus Vinorelbine in Patients With Advanced Breast Cancer, Previously Treated With Anthracyclines and Taxanes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Breast Cancer
Neoplasm Metastasis
Keywords: Drug-resistant metastatic breast cancer
Lead sponsor: Spanish Breast Cancer Research Group
Sponsor class: OTHER
Collaborators: name: Eli Lilly and Company
First posted: 2005-08-09
Enrollment: 252
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a multicenter, randomized, prospective, Phase III study in which patients with advanced breast carcinoma previously treated with anthracyclines and taxanes will be randomly assigned to receive one of two treatment options: vinorelbine (Arm A) or gemcitabine plus vinorelbine (Arm B).

Detailed description: The investigators assume that progression-free survival mean time for patients treated with vinorelbine will be 3 months, and for patients treated with gemcitabine plus vinorelbine will be 5 months. That implies a reduction in risk ratio of 40% (Hazard ratio = 1,67). Assuming a bilateral alpha error of 0.05 and beta error of 10%, and the number of events needed if 60% of patients have progressed after 1 year, the number of patients needed per treatment arm is 114. Considering a 10% post-randomization drop-out, the final number of patients is 252 (126 per arm).

Eligibility criteria: Inclusion Criteria:

* Histological or cytological diagnoses of breast cancer, with metastases.
* Metastatic lesions should not be curable with surgery or radiotherapy.
* Women of age \> 18.
* To have received a previous treatment with anthracyclines and taxanes.
* A maximum of 2 previous chemotherapy treatment lines for metastatic disease.
* Previous radiotherapy is allowed, whenever the radiated area is not the only disease location.
* At least 4 weeks since the last previous antineoplastic treatment; patient must have recovered from all previous toxicities.
* Performance status \< 2 in World Health Organization (WHO) scale.
* Clinically measurable, non measurable or really non measurable disease, as per Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
* Life expectancy of at least 12 weeks.
* Patients able to comply and to receive an adequate follow-up.
* Adequate bone marrow function: neutrophils ≥ 2 x 10\^9/L; platelets ≥ 100 x 10\^9/L; hemoglobin ≥ 100 g/L.
* Calcium within normal limits.
* Premenopausal women must adopt an adequate contraceptive method during the study and up to 3 months after treatment finalization.

Exclusion Criteria:

* Active infection or serious concomitant disease (investigator's criteria).
* Clinical evidence of metastases in the central nervous system (CNS).
* Blastic bone lesions as only disease.
* Previous neurological toxicity grade 3-4 National Cancer Institute (NCI) Common Toxicity Criteria (CTC) v.2.0.
* Previous treatment with gemcitabine and/or vinorelbine.
* More than 2 previous chemotherapy treatment lines for metastatic disease.
* Abnormal liver function (bilirubin \> 2.0-fold upper normal limit (UNL); alanine transaminase (ALT) and aspartate transaminase (AST) \>2.5-fold UNL). In patients with hepatic metastasis, a value of ALT and AST of up to 5-fold UNL is permitted.
* Unpaired renal function (creatinine \> 2.0 mg/dL).
* Pregnancy or lactating.
* Treatment with any investigational agent in the previous 4 weeks.
* Second malignancy (except for cervix carcinoma in situ or skin carcinoma - no melanoma- with an adequate treatment). Previous malignancies are allowed if disease-free survival is superior to 5 years, except for renal carcinoma or melanoma.
* Males.

Primary outcomes:
measure: Progression-free survival
timeFrame: Through study completion, an average of 1 year
Secondary outcomes:
measure: The Number of Participants Who Experienced Adverse Events (AE)
timeFrame: Through study completion, an average of 1 year
measure: Objective Response Rate (ORR)
timeFrame: Through study completion, an average of 1 year
measure: Response Duration (RD)
timeFrame: Through study completion, an average of 1 year
measure: Overall Survival (OS)
timeFrame: Through study completion, an average of 1 year
Other outcomes:
Locations:
city: San Sebastián de los Reyes
country: Spain
facility: Spanish Breast Cancer Research Group (GEICAM)
state: Madrid
city: Valencia
country: Venezuela
facility: Grupo Andino de Investigación en Oncología (GAICO)
Study officials:
affiliation: Hospital San Carlos, Madrid
name: Study Director
role: STUDY_DIRECTOR
References:
citation: Martin M, Ruiz A, Munoz M, Balil A, Garcia-Mata J, Calvo L, Carrasco E, Mahillo E, Casado A, Garcia-Saenz JA, Escudero MJ, Guillem V, Jara C, Ribelles N, Salas F, Soto C, Morales-Vasquez F, Rodriguez CA, Adrover E, Mel JR; Spanish Breast Cancer Research Group (GEICAM) trial. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol. 2007 Mar;8(3):219-25. doi: 10.1016/S1470-2045(07)70041-4.